Equities analysts predict that Corium International Inc (NASDAQ:CORI) will announce ($0.33) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Corium International’s earnings, with estimates ranging from ($0.36) to ($0.29). Corium International posted earnings of ($0.36) per share in the same quarter last year, which suggests a positive year over year growth rate of 8.3%. The company is scheduled to issue its next quarterly earnings results on Thursday, November 15th.

On average, analysts expect that Corium International will report full year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.56) to ($1.50). For the next financial year, analysts anticipate that the business will post earnings of ($1.42) per share, with EPS estimates ranging from ($1.73) to ($1.10). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Corium International.

A number of brokerages recently commented on CORI. BidaskClub upgraded shares of Corium International from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 13th. Needham & Company LLC downgraded shares of Corium International from a “buy” rating to a “hold” rating in a research report on Monday, October 15th. HC Wainwright downgraded shares of Corium International from a “buy” rating to a “neutral” rating and set a $13.00 price objective for the company. in a research report on Monday, October 15th. ValuEngine upgraded shares of Corium International from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 12th. Finally, Zacks Investment Research upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Corium International presently has an average rating of “Hold” and a consensus price target of $13.50.

In other Corium International news, major shareholder Life Sciences Maste Perceptive sold 3,632,447 shares of the stock in a transaction dated Friday, October 12th. The shares were sold at an average price of $12.52, for a total value of $45,478,236.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 30.80% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of CORI. SG Americas Securities LLC purchased a new position in Corium International in the third quarter valued at about $145,000. Man Group plc purchased a new position in Corium International in the third quarter valued at about $163,000. Engineers Gate Manager LP purchased a new position in Corium International in the second quarter valued at about $215,000. Alps Advisors Inc. purchased a new position in Corium International in the second quarter valued at about $420,000. Finally, Schwab Charles Investment Management Inc. increased its holdings in Corium International by 40.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 58,309 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 16,900 shares in the last quarter.

Shares of NASDAQ:CORI opened at $12.65 on Friday. The company has a debt-to-equity ratio of 2.83, a current ratio of 7.61 and a quick ratio of 7.47. The stock has a market capitalization of $458.56 million, a P/E ratio of -7.71 and a beta of 0.87. Corium International has a 52 week low of $7.17 and a 52 week high of $13.93.

Corium International Company Profile

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Read More: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Corium International (CORI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.